The activity of glyoxylase 1 is regulated by glucose-responsive phosphorylation on Tyr136.


Journal

Molecular metabolism
ISSN: 2212-8778
Titre abrégé: Mol Metab
Pays: Germany
ID NLM: 101605730

Informations de publication

Date de publication:
01 2022
Historique:
received: 19 09 2021
revised: 17 11 2021
accepted: 23 11 2021
pubmed: 29 11 2021
medline: 29 3 2022
entrez: 28 11 2021
Statut: ppublish

Résumé

Methylglyoxal (MG) is a highly reactive α-oxoaldehyde that glycates proteins. MG has been linked to the development of diabetic complications: MG is the major precursor of advanced glycation end products (AGEs), a risk marker for diabetic complications in humans. Furthermore, flies and fish with elevated MG develop insulin resistance, obesity, and hyperglycemia. MG is detoxified in large part through the glyoxalase system, whose rate-limiting enzyme is glyoxalase I (Glo1). Hence, we aimed to study how Glo1 activity is regulated. We studied the regulation and effect of post-translational modifications of Glo1 in tissue culture and in mouse models of diabetes. We show that Glo1 activity is promoted by phosphorylation on Tyrosine 136 via multiple kinases. We find that Glo1 Y136 phosphorylation responds in a bimodal fashion to glucose levels, increasing in cell culture from 0 mM to 5 mM (physiological) glucose, and then decreasing at higher glucose concentrations, both in cell culture and in mouse models of hyperglycemia. These data, together with published findings that elevated MG leads to hyperglycemia, suggest the existence of a deleterious positive feedback loop whereby hyperglycemia leads to reduced Glo1 activity, contributing to elevated MG levels, which in turn promote hyperglycemia. Hence, perturbations elevating either glucose or MG have the potential to start an auto-amplifying feedback loop contributing to diabetic complications.

Identifiants

pubmed: 34838714
pii: S2212-8778(21)00264-7
doi: 10.1016/j.molmet.2021.101406
pmc: PMC8715127
pii:
doi:

Substances chimiques

Glycation End Products, Advanced 0
Pyruvaldehyde 722KLD7415
GLO1 protein, human EC 4.4.1.5
Lactoylglutathione Lyase EC 4.4.1.5
Glucose IY9XDZ35W2

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

101406

Subventions

Organisme : NIGMS NIH HHS
ID : R01 GM129325
Pays : United States

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier GmbH.. All rights reserved.

Auteurs

Fabiola Garcia Cortizo (FG)

German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany; Heidelberg University, 69120, Heidelberg, Germany.

Daniel Pfaff (D)

German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany; Department of Internal Medicine I and Clinical Chemistry, University Hospital Heidelberg, Germany.

Angela Wirth (A)

Pharmakologisches Institut, Ruprecht-Karls-Universität Heidelberg, 69120, Heidelberg, Germany.

Andrea Schlotterer (A)

5th Medical Department, Universitätsmedizin Mannheim, University of Heidelberg, Mannheim, Germany.

Rebekka Medert (R)

Pharmakologisches Institut, Ruprecht-Karls-Universität Heidelberg, 69120, Heidelberg, Germany.

Jakob Morgenstern (J)

Department of Internal Medicine I and Clinical Chemistry, University Hospital Heidelberg, Germany; German Center for Diabetes Research (DZD), Neuherberg, Germany.

Tobias Weber (T)

German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany; Heidelberg University, 69120, Heidelberg, Germany.

Hans-Peter Hammes (HP)

5th Medical Department, Universitätsmedizin Mannheim, University of Heidelberg, Mannheim, Germany.

Thomas Fleming (T)

Department of Internal Medicine I and Clinical Chemistry, University Hospital Heidelberg, Germany; German Center for Diabetes Research (DZD), Neuherberg, Germany.

Peter Paul Nawroth (PP)

Department of Internal Medicine I and Clinical Chemistry, University Hospital Heidelberg, Germany.

Marc Freichel (M)

Pharmakologisches Institut, Ruprecht-Karls-Universität Heidelberg, 69120, Heidelberg, Germany.

Aurelio A Teleman (AA)

German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany; Heidelberg University, 69120, Heidelberg, Germany. Electronic address: a.teleman@dkfz.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH